Browse the evidence

Liraglutide, a GLP-1 receptor agonist, improves glycemic control and reduces body weight in type 2 diabetes through glucose-dependent insulin secretion, glucagon suppression, and delayed gastric emptying, with a low risk of hypoglycemia.

Liraglutide is a once-daily injection for type 2 diabetes that helps control blood sugar and promotes weight loss. It works by mimicking a natural hormone (GLP-1) to increase insulin when blood sugar is high and decrease glucagon. Because it only works when blood sugar is elevated, it has a low risk of causing dangerously low blood sugar. Treatment starts at a lower dose to minimize stomach issues, then increases based on how well it controls your blood sugar.

Trans fatty acids (TFAs) from partially hydrogenated oils, commonly found in fast food, are associated with increased risk of coronary heart disease, systemic inflammation, and adverse lipid profiles (increased LDL, decreased HDL).

Industrial trans fats, found in some fast foods, significantly increase the risk of heart disease and worsen cholesterol levels. Avoid foods with partially hydrogenated oils. Look for products with low or zero trans fat content, and prioritize diets rich in unsaturated fats.

Obesity, particularly abdominal-visceral obesity, is a primary risk factor for metabolic syndrome and cardiovascular disease through mechanisms involving insulin resistance, chronic inflammation, and dyslipidemia.

Maintaining a healthy weight, particularly around the abdomen, is crucial for preventing metabolic syndrome and heart disease. This involves managing caloric intake, increasing physical activity, and monitoring blood pressure and lipid levels.

Semaglutide 2.4 mg once weekly improves symptoms, exercise capacity, and reduces inflammation in patients with obesity-phenotype heart failure with preserved ejection fraction (HFpEF) across all obesity classes (BMI 30-34.9, 35-39.9, and ≥40 kg/m²), with clinical benefits directly proportional to the magnitude of weight loss.

If you have heart failure with preserved ejection fraction and obesity, semaglutide (2.4 mg weekly) is a proven treatment that improves your heart symptoms, exercise ability, and inflammation. The more weight you lose, the more you benefit, regardless of whether your obesity is Class I, II, or III. This treatment works best when combined with a moderate caloric deficit (500 kcal/day) and regular physical activity.

Pharmacotherapy is recommended for postmenopausal females and males aged 50+ who have had a previous hip or vertebral fracture, or have a 10-year major osteoporotic fracture risk of 20% or more.

If you are over 50 and have had a hip or vertebral fracture, or have a high 10-year fracture risk (20% or more), you should strongly consider pharmacotherapy. This is a strong recommendation based on high-certainty evidence. Your doctor will help you choose the right medication based on your specific risks and preferences.

Aerobic exercise training significantly improves insulin resistance (HOMA-IR) and fasting serum glucose levels in individuals with Type II Diabetes.

Regular aerobic exercise directly improves how your body uses insulin and lowers your fasting blood glucose levels. This is a key benefit of exercise for managing Type II Diabetes, alongside improving overall fitness and HbA1c.

Ad libitum diets with a low glycemic index (LGI) significantly reduce high-sensitivity C-reactive protein (hsCRP) levels beyond the reduction achieved by weight loss alone, independent of protein content.

If you are trying to lower inflammation markers like CRP after losing weight, prioritize foods with a low glycemic index (like legumes, whole grains, and non-starchy vegetables) over high-glycemic foods (like white bread and sugary snacks). This dietary choice provides an additional anti-inflammatory benefit beyond just maintaining your weight loss.

Exercise therapy significantly lowers glycated haemoglobin (HbA1c) in patients with type 2 diabetes mellitus.

Regular exercise is an effective way to lower blood sugar levels (HbA1c) in type 2 diabetes, reducing the risk of complications.

Exercise therapy lowers blood pressure in hypertensive subjects through aerobic training.

Aerobic exercise is an effective non-pharmacological intervention for lowering blood pressure in people with hypertension.

Liraglutide (3.0 mg daily) is effective for weight loss but significantly less so than Semaglutide, with a mean weight loss of 6.4% compared to 15.8%.

Liraglutide (3.0 mg daily) is an FDA-approved option for weight loss, but it produces roughly half the weight loss of Semaglutide (6.4% vs 15.8%). It requires daily injections, which may be burdensome, and you must reach the 3.0 mg dose to see full effects. If you cannot tolerate Semaglutide, this is a viable alternative, but expect less dramatic results.

Certain anti-diabetic medications, specifically insulin, can increase body weight, creating a conflict in treating obesity and T2DM simultaneously.

If you are prescribed insulin for diabetes, be aware it can cause weight gain. Discuss weight-neutral or weight-loss promoting alternatives (like GLP-1 agonists or SGLT2 inhibitors, though not explicitly named here, implied by 'anti-obesity drugs') with your doctor if weight management is a priority.

Once-weekly semaglutide (2.4 mg) significantly improves heart failure symptoms, physical limitations, and exercise capacity in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) and type 2 diabetes, independent of the magnitude of weight loss.

If you have heart failure with preserved ejection fraction, are obese, and have type 2 diabetes, once-weekly semaglutide (2.4 mg) can significantly reduce your heart failure symptoms and help you lose weight. This treatment works even if your weight loss isn't as dramatic as in people without diabetes, suggesting it helps your heart directly. It is administered as a weekly injection, starting at a low dose to minimize side effects, and titrated up over 16 weeks.

Intensive glycemic control fails to significantly improve cardiovascular outcomes in patients with diabetes, whereas cholesterol-lowering therapy significantly reduces cardiovascular events regardless of baseline lipid profiles.

If you have diabetes, managing your blood sugar is crucial for preventing kidney and eye damage, but it will not significantly protect your heart. To reduce your risk of heart attack or stroke, you must prioritize lowering your LDL cholesterol, even if your levels appear 'normal' on a standard test. Statin therapy is the most effective intervention for cardiovascular prevention in diabetes, regardless of your baseline lipid levels.

Statins are effective for primary and secondary prevention of cardiovascular disease in patients with diabetes, providing significant risk reduction even in patients with low baseline LDL cholesterol.

If you have diabetes, you should likely be on a statin, even if your cholesterol numbers look okay. Statins significantly reduce your risk of heart attack and stroke, and this benefit exists regardless of your baseline LDL. The small risk of developing diabetes from statins is far outweighed by the protection they offer your heart. Discuss high-intensity statins with your doctor if you are over 40 or have other risk factors.

GLP-1 receptor agonists delay gastric emptying, which reduces postprandial lipid and carbohydrate surges and contributes to satiety.

GLP-1 medications slow down how fast food leaves your stomach. This helps you feel full longer and prevents sharp spikes in blood sugar after meals.

GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE), death, and stroke in patients with type 2 diabetes.

If you have type 2 diabetes, GLP-1 receptor agonists can significantly lower your risk of heart attacks, strokes, and death. This benefit is independent of weight loss and is supported by large-scale data involving over 60,000 patients.

GLP-1 receptor agonists (GLP-1RAs) promote sustained weight loss in adults with obesity or type 2 diabetes primarily by increasing energy expenditure and reducing food intake via central nervous system satiety signaling, independent of glycaemic control.

If you have obesity or Type 2 Diabetes, GLP-1 medications like semaglutide or liraglutide are proven to help you lose significant weight (around 15% in trials) by reducing hunger and increasing energy burn. They are taken as a weekly or daily injection, often alongside diet and exercise changes. These are not quick fixes but chronic treatments that mimic a natural gut hormone to help regulate your body's weight set-point.

Once-weekly subcutaneous semaglutide (2.4 mg) significantly alters the circulating proteome in individuals with obesity, downregulating proteins associated with cardiovascular disease risk and inflammatory pathways beyond what is explained by weight loss and glycemic control alone.

If you have obesity and are considering semaglutide, know that it does more than just help you lose weight. It actively changes your blood proteins to lower your risk of heart disease and inflammation, even independent of the weight you lose. This makes it a valuable tool for cardiovascular protection in high-risk individuals, not just a weight-loss aid. The benefits are supported by large, rigorous clinical trials.

SGLT2 inhibitors (empagliflozin) and GLP-1 receptor agonists (liraglutide) significantly reduce cardiovascular mortality and major adverse cardiovascular events (MACE) in high-risk type 2 diabetes patients, unlike earlier glucose-lowering agents which showed neutral or negative effects.

If you have type 2 diabetes and established heart disease, ask your doctor about empagliflozin or liraglutide. These drugs have proven to reduce the risk of heart attack, stroke, and heart failure hospitalization, and even death from cardiovascular causes, beyond just lowering blood sugar. This is particularly relevant if you have kidney issues or heart failure.

Tirzepatide 15mg is associated with a higher rate of adverse events compared to other GLP-1RAs, although not significantly different from placebo in some metrics, it ranks highest in SUCRA for adverse events.

Tirzepatide 15mg is highly effective but comes with a higher risk of side effects like nausea and diarrhea compared to other GLP-1s. Patients should be prepared for this and work with their doctor on dose titration to manage it.

GLP-1 receptor agonists reduce the risk of Major Adverse Cardiovascular Events (MACE) by 13-26% in patients with type 2 diabetes and high cardiovascular risk.

If you have type 2 diabetes and heart disease or high heart risk, GLP-1 medications like semaglutide or liraglutide are recommended not just for blood sugar, but to protect your heart. Studies show they can lower the risk of heart attacks and strokes by 13-26% compared to placebo.

GLP-1 receptor agonists improve cardiovascular outcomes by reducing major adverse cardiovascular events (MACE), including cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, in patients with type 2 diabetes and established cardiovascular disease.

If you have type 2 diabetes and existing heart disease, certain GLP-1 medications (like liraglutide, semaglutide, or dulaglutide) can significantly lower your risk of heart attack, stroke, or cardiovascular death. This benefit is independent of weight loss and is a key reason these drugs are recommended for high-risk patients.

Discontinuation of semaglutide treatment leads to significant weight regain, resulting in net weight loss that is substantially lower than the peak loss achieved during treatment.

If you stop taking semaglutide, you will likely regain most of the weight you lost. The net weight loss after stopping is much smaller than the peak loss. Long-term maintenance may require continued treatment.

GLP-1 receptor agonists (Liraglutide, Semaglutide) and Tirzepatide reduce food intake primarily by increasing satiety and reducing neural activation in brain areas associated with appetite and reward, rather than just delaying gastric emptying.

Semaglutide (2.4 mg weekly) works by acting on your brain to make you feel full sooner and reducing the desire for high-calorie foods. It is not just about stomach emptying. Start with a low dose to minimize side effects, titrating up to 2.4 mg over several months.